Viatris completes $1.65 billion acquisition of Pacira BioSciences
Viatris Inc. closed its purchase of Pacira BioSciences on Nov. 17, 2026, paying $36.50 in cash per share. The tender offer saw 32,929,780 shares, about 66.46% of Pacira’s outstanding stock, accepted and merged into a wholly owned subsidiary. The deal values Pacira at roughly $1.65 billion and will add $90 million‑$100 million of revenue for the remainder of 2026. Pacira’s shares will be delisted from Nasdaq following the merger.
Why it matters
Viatris says the acquisition will contribute $90 million‑$100 million of revenue for Q4 2026, making the transaction immediately accretive to its guidance. The delisting ends Pacira’s public reporting obligations, consolidating its financials under Viatris.
Key facts
- 1Viatris paid $36.50 per Pacira share in cash. prnewswire.com
- 232,929,780 Pacira shares, representing about 66.46% of the outstanding shares, were tendered. prnewswire.com
- 3The equity value of the transaction is approximately $1.65 billion. tokenpost.com
- 4Viatris expects the acquisition to add $90 million to $100 million of revenue for the period Nov. 17‑Dec. 31, 2026. prnewswire.com
- 5Pacira’s shares will be delisted from the Nasdaq Global Select Market. prnewswire.com
- 6Following the tender, Viatris’ subsidiary Peach Purchaser Sub merged into Pacira, making Pacira a wholly owned subsidiary. sec.gov
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.